News
Projects
Orgs
Project
Articles 3
Votes 0
Sarepta.com
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics
~2mo
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS - Sarepta Therapeutics
8mo
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. - Sarepta Therapeutics
8mo